Presage Biosciences logo

Presage Biosciences

presagebio.com

Presage Biosciences develops and offers the CIVO platform, a patented technology that delivers microdoses of multiple drugs directly into different regions of a tumor within a patient to observe molecular and cellular responses. This platform provides detailed insights into the tumor microenvironment, supporting oncology researchers and drug developers in evaluating drug candidates and combinations more effectively. Its mission is to improve cancer drug development and targeting, aiming to provide more effective treatments for patients with cancer.

Facts

HQ
Seattle
Sectors
Biotechnology, Oncology, Life Sciences
Type
Corporation Seattle business license
Registered name
Presage Biosciences Inc Seattle business license
Stage
Seed

Is this your organization? Claim it

Recent coverage

Front-page news, podcasts and videos about Presage Biosciences

Presage Biosciences raises $13M, inks collaborations with Merck and Maverick to test cancer drugs using CIVO

Seattle-based Presage Biosciences raised $13 million in its first venture round, bringing total equity to $35 million, and announced new collaborations with Merck and Maverick Therapeutics to use its CIVO platform for testing cancer drugs in human tumors. The CIVO device enables micro-dosing and biomarker tracking in phase 0 trials, aiming to improve preclinical screening and reduce failures in costly phase I trials.

Online

Questions about Presage Biosciences

What is Presage Biosciences?

presagebio.com

Who invested in Presage Biosciences, and how much has it raised?

Members of Seattle Flow see Presage Biosciences' funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Presage Biosciences based?

Presage Biosciences is headquartered in Seattle.

When was Presage Biosciences founded?

Presage Biosciences was founded in 2010.